US20080187602A1 - Stabilized lanthanum carbonate compositions - Google Patents

Stabilized lanthanum carbonate compositions Download PDF

Info

Publication number
US20080187602A1
US20080187602A1 US12/100,224 US10022408A US2008187602A1 US 20080187602 A1 US20080187602 A1 US 20080187602A1 US 10022408 A US10022408 A US 10022408A US 2008187602 A1 US2008187602 A1 US 2008187602A1
Authority
US
United States
Prior art keywords
lanthanum carbonate
hydrated
weight
lanthanum
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/100,224
Inventor
Josephine Christine Ferdinando
Petet Neil Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire International Licensing BV
Original Assignee
Shire International Licensing BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080187602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/926,330 external-priority patent/US7465465B2/en
Application filed by Shire International Licensing BV filed Critical Shire International Licensing BV
Priority to US12/100,224 priority Critical patent/US20080187602A1/en
Publication of US20080187602A1 publication Critical patent/US20080187602A1/en
Assigned to SHIRE INTERNATIONAL LICENSING B.V. reassignment SHIRE INTERNATIONAL LICENSING B.V. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE CHANGE OF ADDRESS NEW ADDRESS: 2250 ALFRED-NOBEL BOULEVARD, SUITE 500, ST-LAURENT, QUEBEC, CANADA H4S2C9 PREVIOUSLY RECORDED ON REEL 020890 FRAME 0912. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST IN AND TO SAID INVENTION AND ANY RENEWALS, REISSUES, REEXAMINATION AND EXTENSIONS THEREOF.. Assignors: DAVIES, PETER NEIL, FERDINANDO, JOSEPHINE CHRISTINE
Assigned to SHIRE INTERNATIONAL LICENSING B.V. reassignment SHIRE INTERNATIONAL LICENSING B.V. CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION OF APPLICANT'S ADDRESS TO: STRAWINSKYLAAN 847 1077 XX AMSTERDAM THE NETHERLANDS PREVIOUSLY RECORDED ON REEL 020890 FRAME 0912. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST IN AND TO SAID INVENTION AND ANY RENWALS, REISSUES, REEXAMINATION AND EXTENSIONS THEREOF.. Assignors: DAVIES, PETER NEIL, FERDINANDO, JOSEPHINE CHRISTINE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • This invention relates to stabilized lanthanum carbonate compositions comprising a monosaccharide or disaccharide stabilizing agent, and to the treatment of subjects having hyperphosphatemia by administering a pharmaceutical composition containing a therapeutically effective amount of a stabilized lanthanum carbonate composition.
  • Hyperphosphatemia is a particular problem of patients with chronic renal insufficiency or chronic kidney disease (CKD). Approximately 70% of patients with end stage renal disease (ESRD) on renal dialysis therapy require treatment for hyperphosphatemia. This condition can lead to severe bone problems and metastatic calcification of skin and major organs and is associated with significant morbidity and mortality. Conventional dialysis fails to reduce the levels of phosphate in the blood, so that levels rise in time. Elevated phosphate levels are treated using a combination of dietary restrictions and phosphate-binding agents.
  • Another problem of patients with chronic renal insufficiency is secondary hyperparathyroidism. It is also important in patients with chronic renal insufficiency to avoid and treat secondary hyperparathyroidism.
  • Certain forms of lanthanum carbonate have been used to treat hyperphosphatemia in patients with renal failure (see, e.g., JP 1876384).
  • lanthanum carbonate has a tendency to degrade to lanthanum hydroxycarbonate. This process is accelerated by moisture and heat. There is a need in the art to prevent this degradation because current regulatory requirements preclude detectable decarboxylation for administration to patients.
  • the present invention is based on the surprising finding that monosaccharides or disaccharides significantly retard the degradation of lanthanum carbonate, whereas more complex saccharides (e.g., corn starch and ⁇ -cyclodextrins) do not.
  • Stabilized compositions of lanthanum carbonate can be used in pharmaceutical preparations and for treating subjects having hyperphosphatemia.
  • a stabilized lanthanum carbonate composition comprising a pharmaceutically effective amount of lanthanum carbonate having the general formula La 2 (CO 3 ) 3 .xH 2 O wherein x has a value from 0 to 10, and at least one pharmaceutically acceptable monosaccharide or disaccharide, wherein the monosaccharide or disaccharide is present in an amount of at least about 1% by weight based on the total weight of the composition.
  • the invention is applicable to the treatment of subjects susceptible to or suffering from hyperphosphatemia, at risk for chronic kidney disease (CKD), having stage one to five CKD, susceptible to or suffering from soft tissue calcification associated with CKD, susceptible to or suffering from secondary hyperparathyroidism, or susceptible to or suffering from other as yet undiscovered conditions requiring control of phosphate absorption.
  • This invention is also applicable to the treatment of subjects described in U.S. application Ser. No. ______ entitled “Treatment of Chronic Kidney Disease (CKD) Subjects using Lanthanum Compounds” filed on the same day as the present application.
  • Lanthanum carbonate in the form of a chewable tablet which is one embodiment of the present invention (available as Fosrenol® from Shire Pharmaceuticals, Wayne, Pa.) has been approved by the FDA to treat hyperphosphatemia in ESRD subjects and it currently being marketed.
  • FIG. 1 is an XRPD (x-ray powder diffraction) pattern of substantially pure hydrated lanthanum carbonate having a water content approximately equivalent to 4-5 moles of water.
  • FIG. 2 illustrates XRPD patterns of substantially pure corn starch, ⁇ -cyclodextrin, dextrates, D-sorbitol, D-mannitol, and anhydrous lanthanum carbonate.
  • FIG. 3 illustrates XRPD patterns of hydrated lanthanum carbonate at 60° C./95% RH (relative humidity) for 0, 1, 2, 3, 4, and 7 days.
  • FIG. 4 illustrates XRPD patterns of hydrated lanthanum carbonate at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 5 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/D-mannitol at 60° C./65% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 6 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/D-sorbitol at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 7 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/dextrates at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 8 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/p-cyclodextrin at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 9 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/corn starch at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 10 illustrates XRPD patterns of a 1:1 (by weight) mixture of anhydrous lanthanum carbonate/D-mannitol at 60° C./95% RH for 0, 1, 2, 3, 4, and 7 days.
  • FIG. 11 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/anhydrous lactose at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 12 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/lactose monohydrate at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 13 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/microcrystalline cellulose at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 14 illustrates the XRPD patterns of a 96:4 (by weight) mixture of hydrated lanthanum carbonate/D-mannitol at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 15 shows the degradation to lanthanum hydroxycarbonate that occurs in unformulated hydrated lanthanum carbonate and formulated hydrated lanthanum carbonate containing approximately 50% (by weight) dextrates at 25° C./60% RH, 30° C./60% RH, and 40° C./75% RH for up to 24 months.
  • the terms “treat,” “treating,” or “treatment” mean the prevention, reduction, amelioration, partial or complete alleviation, or cure of hyperphosphatemia, chronic kidney disease (CKD), severe bone problems, soft tissue calcification, secondary hyperparathyroidism, or other as yet undiscovered conditions requiring control of phosphate absorption.
  • the term “subject” refers to a mammal (e.g., any veterinary medicine patient such as a domesticated animal, such as a dog or cat), or a human patient.
  • extract refers to a purified mixture of saccharides that is mostly dextrose (e.g., not less than about 93.0% and not more than about 99.0%, calculated on the dried basis) and that results from a controlled enzymatic hydrolysis of starch. Dextrates can be either anhydrous or hydrated. “Dextrates” can refer to dextrates as defined its official monograph found in National Formulary 21 (printed by Webcom Limited in Toronto, Canada; 2003). Dextrates are available from JRS Pharma (Patterson, N.Y.) as Emdex®.
  • a “stabilized composition” or “stabilized lanthanum carbonate composition” refers to a composition containing lanthanum carbonate (of any hydration state including anhydrous lanthanum carbonate) and one or more monosaccharides or disaccharides. Preferably, the total amount of monosaccharides, disaccharides, or combination thereof is present in the stabilized composition in an amount of at least about 1% by weight.
  • the lanthanum carbonate in a stabilized lanthanum carbonate composition degrades into lanthanum hydroxycarbonate at a slower rate compared to lanthanum carbonate alone or not in the presence of other materials. For example, after 7 days at 60° C.
  • lanthanum carbonate in a lanthanum carbonate composition stabilized with at least about 4% monosaccharide, disaccharide, or combination thereof does not detectably (by present analytical techniques) degrade into lanthanum hydroxycarbonate.
  • substantially pure lanthanum carbonate begins to decompose into lanthanum hydroxycarbonate after only 1 day.
  • a “pharmaceutically effective amount” or “therapeutically effective amount” as used herein is an amount or dose of lanthanum carbonate sufficient (i) to detectably decrease the serum phosphate levels of a subject or (ii) at a minimum, to keep the serum phosphate levels of a subject substantially constant.
  • “Lanthanum carbonate” as used herein encompasses all hydrated forms of lanthanum carbonate as well as anhydrous lanthanum carbonate.
  • Percent or “%” as used herein refers to the percentage by weight of the total composition.
  • substantially pure lanthanum carbonate refers to lanthanum carbonate of about 90% purity or greater, on an anhydrous basis.
  • symptom(s) of those at risk for or having hyperphosphatemia, CKD, soft tissue calcification associated with CKD, or secondary hyperparathyroidism may be any functional or structural abnormality experienced by a subject and indicating kidney dysfunction, e.g., those described in Section 5.6, infra.
  • one or more of the following symptoms may indicate risk for or the presence of CKD: a creatinine concentration of above about 1.6 mg/dL, a blood urea nitrogen (BUN) of above about 20 mg/dL, a blood phosphate level of above about 4.5 mg/dL, any detectable amount of blood in the urine, a urine protein concentration above about 100 mg/dL, a urine albumin concentration above about 100 mg/dL, an intact parathyroid hormone (PTH) concentration in the blood of above about 150 pg/mL, or a glomerular filtration rate (GFR) of below about 90 mL/min/1.73 m 2 .
  • BUN blood urea nitrogen
  • PTH parathyroid hormone
  • GFR glomerular filtration rate
  • the stabilized compositions of the invention can contain lanthanum carbonate having the general formula La 2 (CO 3 ) 3 .xH 2 O, wherein x has a value from 0 to 10.
  • x has a value from 3 to 8, desirably from 3 to 6.
  • x may have an average value of about between 4 and 5.
  • the hydration level of the lanthanum compound can be measured by methods well known in the art, such as thermo gravimetric analysis (TGA) or x-ray powder diffraction (XRPD).
  • the hydroxycarbonate product results from electrophilic or nucleophilic attack on the carbonyl moiety of lanthanum carbonate. This process is accelerated in the presence of moisture or heat and appears to be self-catalyzing. Hence, even a very small amount of lanthanum hydroxycarbonate in lanthanum carbonate formulations causes rapid and excessive degradation. Furthermore, there is a need in the art to prevent this degradation since, as noted above, current regulatory requirements preclude detectable decarboxylation for administration to patients. As a result, formulations that eliminate or substantially retard degradation are highly preferred.
  • the presence of at least about 1% by weight of one or more monosaccharides or disaccharides in the lanthanum carbonate composition significantly retards the degradation of lanthanum carbonate.
  • the addition of such a stabilizing agent is effective to minimize degradation irrespective of the degree of hydration (if any) of the lanthanum carbonate.
  • a mono- or disaccharide about 70% by weight
  • substantially no detectable degradation occurs for up to or more than 3 years under standard ambient conditions.
  • the stabilizing effect of the monosaccharide and disaccharide stabilizing agents of this invention is believed to be attributed to the availability of reactive alcohol —OH groups on such materials; on the other hand, polysaccharides (wherein the alcohol groups are further reacted to link the monosaccharide units) do not exhibit such stabilizing characteristics. Water reacts preferentially with the available alcohol groups on the monosaccharides or disaccharides, leaving the carbonyl groups of the lanthanum carbonate intact so that the anti-hyperphosphatemic agent is not degraded.
  • the degradation of lanthanum carbonate into lanthanum hydroxycarbonate can be observed by examining an x-ray powder diffraction (XRPD) pattern of a potentially degraded lanthanum carbonate sample.
  • XRPD x-ray powder diffraction
  • Example 5 demonstrates the use of XRPD patterns to observe the degradation of lanthanum carbonate into lanthanum hydroxycarbonate.
  • Additional advantages of the instant invention include, but are not limited to, less expensive storage and handling costs due to a diminished need to refrigerate the stabilized lanthanum carbonate formulations.
  • the stabilized formulations also provide enhanced product shelf-life resulting in less waste due to outdated product inventory.
  • the stabilized compositions of the invention contain at least one monosaccharide or disaccharide.
  • the monosaccharide, disaccharide, or mixture thereof is present in a total amount of at least about 1%, preferably from about 4% to about 90%, and more preferably from about 30% to about 70% by weight of the composition.
  • Suitable monosaccharides for use as stabilizing agents in the formulation of the present invention include, but are not limited to, glyceraldehyde, erythrose, threose, ribose, lyxose, xylose, arabinose, allose, talsoe, gulose, mannose, glucose (e.g., in the form of corn syrup), idose, galactose, altrose, dihydroxyacetone, erythrulose, ribulose, xyloketose, psicose, tagatose, sorbose, fructose, sorbitol, xylitol, inositol, erythritol, and mannitol in either the D- or L-configuration, including derivatives and analogs thereof.
  • Monosaccharides for use in this inventions can be either cyclic (in either ⁇ - or ⁇ -form) or acyclic and can be used in the invention as mixtures.
  • Other suitable monosaccharides include dextrose (D-glucose such as Cerelose® available from Fisher Scientific (Hampton, N.H.)).
  • Suitable disaccharides for use as stabilizers in the present invention include, but are not limited to, sucrose (for example, in the form of Di-Pac® available from Domino Foods in Baltimore, Md., Sugartab® available from JRS Pharma (Patterson, N.Y.), confectioner's sugar, or Nutab), lactose (including anhydrous lactose and lactose monohydrate), maltose, isomaltose, cellobiose, trehalose, maltitol (in the form of Lycasin® available from Roquette (Lestrem, France)), isomalt, lactitol, mixtures, dervatives, and analogs thereof.
  • sucrose for example, in the form of Di-Pac® available from Domino Foods in Baltimore, Md.
  • Sugartab® available from JRS Pharma (Patterson, N.Y.), confectioner's sugar, or Nutab
  • lactose including anhydrous lactose and lactose monohydrate
  • Disaccharides of this invention also include any combination of two monosaccharides linked by a glycosidic bond.
  • Disaccharides can be either homodisaccharides (i.e., consisting of 2 monosaccharides that are the same) or heterodisaccharides (i.e., consisting of 2 monosaccharides that are different).
  • monosaccharides and disaccharides can be used in the same formulation.
  • Dextrates or sorbitol are preferably used as the monosaccharide or disaccharide stabilizing agent, in an amount preferably from about 4% to about 90% by weight of the formulation.
  • dextrates is incorporated as the stabilizing agent in an amount of about 70% by weight of the formulation.
  • sorbitol is incorporated as the stabilizing agent in an amount of about 30% by weight of the formulation.
  • the stabilized formulations of the invention may further comprise at least one excipient.
  • the excipients used in the formulation administered by the present invention should be suitable for oral administration to renally impaired subjects
  • the excipients may include diluents, binders, and lubricants/glidants. Other agents such as disintegrants, colors, and flavors/sweeteners can be added to the formulation.
  • Suitable diluents can be chosen from, for example, calcium sulfate dihydrate, oligosaccharide, isomaltooligosaccharide, erythritol, polydextrose, dextrins, starch, maltodextrin, calcium lactate trihydrate, microcrystalline cellulose (such as Avicel® available from GFS Chemicals (Powell, Ohio)), hydrolyzed cereal solids (such as Maltrons or Mor-RexTM), amylose, or glycine. Additional diluents can include the mono- and disaccharides stabilizing agents discussed, supra.
  • One or more diluents can be present in a formulation.
  • the total diluent amount can be from about 1% to about 90%, preferably from about 4% to about 90%, and most desirably from about 40% to about 80% by weight of the composition.
  • Useful lubricants can be chosen from, for example, magnesium stearate, talc, polyethylene glycol, silica, colloidal anhydrous silica, colloidal silicon dioxide, hydrogenated vegetable oil, glyceryl behenate or glyceryl monostearate.
  • One or more lubricants can be present in a formulation.
  • the total lubricant amount can be from about 0.1% to about 6.0%, preferably from about 0.1% to about 5.0%, and most desirably from about 0.1% to about 4.0% by weight of the composition.
  • Useful glidants can be chosen from, for example, silica, colloidal anhydrous silica, colloidal silicon dioxide, or talc.
  • One or more glidants can be present in a formulation.
  • the total glidant amount can be from about 0.1% to about 6.0%, preferably from about 0.1% to about 5.0%, and most desirably from about 0.1% to about 4.0% by weight of the composition.
  • antioxidants for example, ascorbic acid, alpha tocopherol or butylated hydroxyanisole
  • the total antioxidant amount can be from about 0.0001% to 1.0%, preferably from about 0.001% to about 0.1%, and most desirably from about 0.005% to 0.05% by weight of the composition.
  • a subject suffering from hyperphosphatemia or the symptoms of CKD is also vitamin D deficient.
  • Levels of 25-hydroxy vitamin D 2 are low at values less than about 16 ng/mL and replacement treatment aims for levels of greater than or equal to about 16 ng/mL.
  • Levels of 1,25-dihydroxy vitamin D2 are low at values less than about 22 pg/mL and replacement treatment aims for levels of greater than about 22 pg/mL.
  • vitamin D sources which may be used in a formulation of this invention include 1,25 dihydroxy-vitamin D, the active metabolite of vitamin D (ealcitriol, rocalcitrol).
  • suitable vitamin D analogs include doxercalciferol (Hectorole, available from Bone Care International, Middleton, Wis.) and paricalcitol (Zemplar®, available from Abbott Laboratories, Abbott Park, Ill.).
  • One or more vitamin D sources or vitamin D analogs can be present in a formulation.
  • Vitamin D can also be administered in a separate dosage form, but concurrently with the dosage form of this invention.
  • 100 USP units of vitamin D is administered once per day and 250 mg of the stabilized lanthanum carbonate formulation is administered three times per day to a patient requiring treatment.
  • a formulation of the invention can include lanthanum carbonate and a calcium source.
  • Examples of forms of calcium include calcium carbonate (e.g., Tums® available from GlaxoSmithKline, Uxbridge, UK), calcium acetate (e.g., PhosLo® available from Nabi Biopharmaceuticals, Boca Raton, Fla.), and CaCl 2 .
  • One or more calcium sources can be present in a formulation.
  • a calcium source can also be administered in a separate dosage form, but concurrently with the dosage form of this invention.
  • 1-2 tablets containing 200 mg as calcium and 250 mg of the stabilized lanthanum carbonate formulation are each given 3 times per day to a patient requiring treatment.
  • a subject suffering from hyperphosphatemia or the symptoms of CKD can be vitamin K deficient.
  • the formulation of the invention, in combination with vitamin K is administered to a subject suffering from hyperphosphatemia or the symptoms of CKD to alleviate vitamin K deficiency.
  • vitamin K sources examples include vitamin K1 (phylloquinone), vitamin K2 (menaquinone), and vitamin K3 (menadione).
  • Vitamin K can be combined in the same formulation as the lanthanum formulation or can be given in a different formulation. In a specific embodiment, 2.5 to 25 mg of vitamin K1 are administered once per day and a lanthanum formulation is administered three times per day to a subject requiring treatment.
  • Subjects susceptible to or suffering from hyperphosphatemia, at risk for chronic kidney disease (CKD), having stage one to five CKD, susceptible to or suffering from soft tissue calcification associated with CKD, susceptible to or suffering from secondary hyperparathyroidism, or susceptible to or suffering from other as yet undiscovered conditions requiring control of phosphate absorption, can be treated by administering a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present invention.
  • CKD chronic kidney disease
  • CKD chronic kidney disease
  • soft tissue calcification associated with CKD susceptible to or suffering from soft tissue calcification associated with CKD
  • susceptible to or suffering from secondary hyperparathyroidism susceptible to or suffering from other as yet undiscovered conditions requiring control of phosphate absorption
  • kidney disease has defined chronic kidney disease (CKD) as either (1) having kidney damage as defined by structural or functional abnormalities of the kidney for 3 months or longer with or without a decreased glomerular filtration rate (GFR) or (2) having a GFR of less than 60 mL/min/1.73 m 2 for 3 months or longer with or without kidney damage.
  • CKD chronic kidney disease
  • GFR glomerular filtration rate
  • Structural or functional abnormalities are manifested by symptoms such as either pathologic abnormalities or markers of kidney damage, including abnormalities identified in imaging studies or the composition of blood or urine.
  • markers of kidney damage include a plasma creatinine concentration of above about 1.6 mg/dL and a blood urea nitrogen (BUN) concentration of above about 20 mg/dL. Typically, both of these markers are elevated in individuals with CKD. Additional markers of kidney damage can include hematuria (i.e., any detectable amount of blood in the urine), proteinuria (i.e., protein concentrations in urine above about 100 mg/dL), albuminuria (i.e., albumin concentrations in urine above about 100 mg/dL), an intact parathyroid hormone (PTH) concentration in the blood above about 150 pg/mL, or blood phosphate levels of above about 4.5 mg/dL.
  • One specific marker of kidney disease is a GFR rate above normal (i.e., a GFR above about 90 mL/min/1.73 m 2 ), however a below normal GFR also indicates CKD.
  • K/DOQI has published guidelines that define five different stages of CKD ( Am J Kidney Dis. 2001, 37(suppl 1):S1-S238).
  • the following table provides a description of each of the five stages of CKD and the GFR ranges for each of the stages.
  • Hyperphosphatemia in CKD subjects has several secondary effects. When a subject suffers from hyperphosphatemia, excess serum phosphate precipitates serum calcium causing widespread ectopic extraskeletal calcification. Unwanted calcium deposits can occur in cardiovascular tissue, resulting in an increased risk of cardiovascular complications that often lead to death. Additionally, increased serum phosphate decreases intestinal calcium absorption. These two mechanisms work concurrently to reduce serum calcium levels.
  • a reduction in serum calcium levels can contribute to an increase in the production of parathyroid hormone (PTH) and to the development of secondary hyperparathyroidism. Furthermore, recent studies show that high phosphate levels can stimulate PTH production directly and lead to secondary hyperparathyroidism. Continual stimulation of PTH secretion induces hyperplasia of the parathyroid gland and may lead to a parathyroidectomy becoming necessary.
  • PTH parathyroid hormone
  • the method of the present invention involving the administration of a stabilized lanthanum carbonate formulation not only reduces plasma phosphate levels but ameliorates the effects of CKDCl in subjects susceptible to or having any of stages one to five CKD, including hyperphosphatemia, ectopic extraskeletal calcification, serum hypocalcemia, and secondary hyperparathyroidism. It should however, be understood that this invention is not limited to any particular biochemical or physiological mechanism.
  • Hyperphosphatemia refers to a condition of a patient having blood phosphate levels of above about 4.5 mg/dL.
  • a subject having a symptom or symptoms of chronic kidney disease can be treated by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present application.
  • the subject treated may be at risk for CKD or have any of stages one to five CKD as defined above.
  • Subjects at risk for CKD or who have any of stages one to five CKD who may be treated may have one or more of the following symptoms: a blood phosphate level of above about 4.5 mg/dL, a plasma creatinine concentration of above about 1.6 mg/dL, a BUN of above about 20 mg/dL, any detectable amount of blood in the urine, a urine protein concentration above about 100 mg/dL, a urine albumin concentration above about 100 mg/dL, an intact parathyroid hormone concentration in the blood above about 150 pg/mL, an abnormal GFR, or combination thereof.
  • the present method may be utilized to prevent the progression of renal pathology, e.g., by treating a subject displaying one or more symptoms of stage one CMD to prevent the development of CKD in the subject or by treating a subject having stage one CM) to prevent progression of the disease to stage two CKD, and so on.
  • a subject having a symptom or symptoms of CKD can be treated for calcification of soft tissue associated with CKD by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present invention.
  • Calcification can occur in any soft tissue.
  • Soft tissue can include arterial tissue, cardiac muscle, heart valves, joints, skin and breast tissue.
  • a subject suffering from or having one or more symptoms of secondary hyperparathyroidism can be treated by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present application.
  • Hyperparathyroidism is defined as a disease in a subject having an intact PTH level of about 150 pg/mL or greater.
  • the symptoms of hyperparathyroidism include hypocalcaemia (i.e., a blood calcium level below about 8.5 mg/dL), hyperphosphatemia (i.e., a blood phosphate level of above about 4.5 mg/dL), and bone disorders (e.g., bone fractures or bone pain).
  • the lanthanum carbonate formulation can be orally administered to subjects in accordance with this invention in dosage forms varying from about 125 to about 2000 mg lanthanum carbonate as elemental lanthanum per meal.
  • a typical dosage for an adult can be, e.g., 375 mg-6000 mg daily. More preferably, the dosage is 375-3750 mg/day.
  • the dose can be divided and taken with each meal, for example a 250, 500, 750, or 1000 mg tablet, e.g., three times per day.
  • Serum plasma levels can be monitored weekly and dosages can be modified until an optimal serum phosphate level is reached.
  • Administration may be conducted in an uninterrupted regimen; such a regimen may be a long term regimen, e.g., a permanent regimen, for treating chronic conditions.
  • the lanthanum carbonate formulations can be orally administered, for example, in the form of tablets, capsules, chewable formulations, or the like. Frequently, due to their renal problems, subjects with hyperphosphatemia need to limit their liquid intake. Therefore, a lanthanum carbonate formulation that can be taken with no or limited amounts of liquid is desirable.
  • a lanthanum carbonate formulation in the form of, e.g., beads, chewed or crushed tablets, powder, or sieved granules, may be sprinkled on food.
  • the lanthanum carbonate formulation is administered such that plasma levels of lanthanum are low, e.g., at least as low as those provided by a mean concentration curve where C max , T max and AUC are preferably less than 1.5 ng/ml, about 12 hours, and less than 50 ng ⁇ hr/ml, respectively, for a dose of 3 g per day (e.g., 1 g three times per day).
  • the C max and AUC are less than 1.1 ng/ml and less than 32 ng ⁇ hr/ml, and desirably, C max and AUC are less than 0.5 ng/ml and less than 20 ng ⁇ hr/ml, for such dosage.
  • T max values are essentially unaffected by dose and C max and AUC values vary linearly with dosage for oral dosages up to about 1500 mg/day. C max and AUC values plateau for dosages above about 1500 mg/day. All of these parameters have their common meanings.
  • lanthanum carbonate formulation and the duration of the treatment will vary depending on the requirements for treatment of individual subjects.
  • the precise dosage regimen will be determined by the attending physician or veterinarian who will, inter alia, consider factors such as body weight, age and specific symptoms.
  • the physician or veterinarian may titrate the dosage of lanthanum carbonate administered to a subject to determine the correct dosage for treatment. For example, a physician can measure phosphate levels in a patient, prescribe a particular lanthanum carbonate dosage to the patient for a week, and evaluate after the week if the dosage is appropriate by remeasuring phosphate levels in the patient.
  • hydrated lanthanum carbonate refers to lanthanum carbonate having a water content approximately equivalent to 4-5 moles of water.
  • the manufacturing process involves sieving and blending the active ingredient with the excipients followed by direct compression. More specifically the steps are as follows:
  • Blend the lanthanum carbonate and the excipients e.g., dextrates, colloidal silicon dioxide, talc (optional) and magnesium stearate.
  • Formulation B 250 mg 500 mg 750 mg tablet tablet tablet 1000 mg tablet Tablet diameter Formulation 13 mm 18 mm 20 mm 22 mm
  • Formulation C Percent by Weight Formulation Components in the Tablet Hydrated lanthanum carbonate 45.8% Colloidal silicon dioxide (e.g., Aerosil ® 2.1% 200 available from Degussa Corp. (Piscataway, NJ)) Dextrates 51.1% Magnesium sterate 1.0%
  • the following lanthanum carbonate chewable tablet formulation comprising sorbitol can be manufactured as described in Example 1.
  • the following lanthanum carbonate chewable tablet formulation comprising mannitol can be manufactured as described in Example 1.
  • the following lanthanum carbonate chewable tablet formulation comprising xylitol can be manufactured as described in Example 1.
  • Test excipients D-mannitol, D-sorbitol, dextrates, ⁇ -cyclodextrin, corn starch, anhydrous lactose, lactose monohydrate, and microcrystalline cellulose were purchased from commercial suppliers and used as received.
  • XRPD analyses were performed using a Shimadzu XRD-6000 X-ray powder diffractometer using Cu K ⁇ radiation. Samples were prepared for analysis by placing them in an aluminum holder with a silicon insert.
  • the unstressed, substantially pure hydrated lanthanum carbonate was crystalline by XRPD ( FIG. 1 ).
  • Excipients and anhydrous lanthanum carbonate used in this study were characterized by XRPD for specificity purposes, and their patterns are displayed in FIG. 2 . All excipients exhibit sufficient specificity to allow the monitoring of lanthanum hydroxycarbonate (HC) formation.
  • HC lanthanum hydroxycarbonate
  • the hydrated lanthanum carbonate was stressed under two conditions, 60° C./95% RH and 60° C./65% RH, in order to establish a baseline for monitoring decarboxylation. Individual samples were pulled after 1, 2, 3, 4, and 7 days and immediately analyzed by XRPD. In addition, pulls were made at 14 and 21 days under the 60 C/65% RH condition.
  • FIG. 3 60° C./95% RH conditions
  • FIG. 4 60° C./65% RH conditions summarize the results.
  • the decarboxylation product, HC was initially seen after one day.
  • HC was again initially seen after a single day ( FIG. 4 ).
  • the 1:1 (by weight) mixtures of hydrated lanthanum carbonate/ ⁇ -cyclodextrin were stressed and analyzed over a two week period.
  • the results are summarized in FIG. 8 .
  • the presence of the decarboxylation product HC was initially detected after 1 day of stressing.
  • the 1:1 (by weight) mixtures of hydrated lanthanum carbonate/corn starch were set up for stressing over a two week period.
  • the results are summarized in FIG. 9 .
  • the presence of the decarboxylation product HC was initially detected after 1 day of stressing.
  • the 1:1 (by weight) mixture of hydrated lanthanum carbonate/microcrystalline cellulose showed evidence of the decarboxylation of hydrated lanthanum carbonate after a single day of stressing at 60° C. and 95% relative humidity.
  • the results are summarized in FIG. 13 .
  • Unformulated hydrated lanthanum carbonate and formulated hydrated lanthanum carbonate tablets containing approximately 50% (by weight) dextrates were exposed to the standard ICH stability conditions of 25° C./60% RH, 30° C./60% RH and 40° C./75% RH for a period up to 2 years. Samples were removed periodically over this time and tested for their lanthanum hydroxycarbonate content using x-ray powder diffraction.
  • FIG. 15 shows the decarboxylation rates of unformulated hydrated lanthanum carbonate and demonstrates significant degradation of the unformulated hydrated lanthanum carbonate at the standard ICH stability conditions of 25° C./60% RH, 30° C./60% RH and 40° C./75% RH.
  • the degradation at the 25° C./60% RH condition results indicates the need to store the unformulated drug substance in refrigerated conditions in order to slow the degradation rate.
  • no decarboxylation can be detected in similarly stored tablets formulated with about 50% (by weight) dextrates as shown in FIG. 15 .

Abstract

Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.

Description

  • This application is a continuation of U.S. application Ser. No. 11/272,569, filed Nov. 9, 2005, which is a continuation in part (CIP) of U.S. application Ser. No. 10/926,330, entitled “Pharmaceutical Formulation Comprising Lanthanum Compounds” filed Aug. 26, 2004, and published as U.S. publication No. 2005/0079135 on Apr. 14, 2005, which claims priority to U.S. Provisional application No. 60/497,560, filed Aug. 26, 2003, and U.S. Provisional application No. 60/517,078, filed Nov. 5, 2003. U.S. application Ser. No. 11/272,569, U.S. application Ser. No. 10/926,330, Provisional application No. 60/497,560, and Provisional application No. 60/517,078 are each incorporated by reference herein.
    • 1. FIELD OF THE INVENTION
  • This invention relates to stabilized lanthanum carbonate compositions comprising a monosaccharide or disaccharide stabilizing agent, and to the treatment of subjects having hyperphosphatemia by administering a pharmaceutical composition containing a therapeutically effective amount of a stabilized lanthanum carbonate composition.
    • 2. BACKGROUND OF THE INVENTION
  • Hyperphosphatemia is a particular problem of patients with chronic renal insufficiency or chronic kidney disease (CKD). Approximately 70% of patients with end stage renal disease (ESRD) on renal dialysis therapy require treatment for hyperphosphatemia. This condition can lead to severe bone problems and metastatic calcification of skin and major organs and is associated with significant morbidity and mortality. Conventional dialysis fails to reduce the levels of phosphate in the blood, so that levels rise in time. Elevated phosphate levels are treated using a combination of dietary restrictions and phosphate-binding agents.
  • Another problem of patients with chronic renal insufficiency is secondary hyperparathyroidism. It is also important in patients with chronic renal insufficiency to avoid and treat secondary hyperparathyroidism.
  • Certain forms of lanthanum carbonate have been used to treat hyperphosphatemia in patients with renal failure (see, e.g., JP 1876384).
  • U.S. Pat. No. 5,968,976, owned by the assignee of the present invention, describes the preparation and use in a pharmaceutical composition of certain hydrates of lanthanum carbonate for the treatment of hyperphosphatemia.
  • However, lanthanum carbonate has a tendency to degrade to lanthanum hydroxycarbonate. This process is accelerated by moisture and heat. There is a need in the art to prevent this degradation because current regulatory requirements preclude detectable decarboxylation for administration to patients. The present invention is based on the surprising finding that monosaccharides or disaccharides significantly retard the degradation of lanthanum carbonate, whereas more complex saccharides (e.g., corn starch and β-cyclodextrins) do not. Stabilized compositions of lanthanum carbonate can be used in pharmaceutical preparations and for treating subjects having hyperphosphatemia.
    • 3. SUMMARY OF THE INVENTION
  • In accordance with the present invention, a stabilized lanthanum carbonate composition is provided, comprising a pharmaceutically effective amount of lanthanum carbonate having the general formula La2(CO3)3.xH2O wherein x has a value from 0 to 10, and at least one pharmaceutically acceptable monosaccharide or disaccharide, wherein the monosaccharide or disaccharide is present in an amount of at least about 1% by weight based on the total weight of the composition. As indicated hereinafter, the invention is applicable to the treatment of subjects susceptible to or suffering from hyperphosphatemia, at risk for chronic kidney disease (CKD), having stage one to five CKD, susceptible to or suffering from soft tissue calcification associated with CKD, susceptible to or suffering from secondary hyperparathyroidism, or susceptible to or suffering from other as yet undiscovered conditions requiring control of phosphate absorption. This invention is also applicable to the treatment of subjects described in U.S. application Ser. No. ______ entitled “Treatment of Chronic Kidney Disease (CKD) Subjects using Lanthanum Compounds” filed on the same day as the present application.
  • Lanthanum carbonate in the form of a chewable tablet which is one embodiment of the present invention (available as Fosrenol® from Shire Pharmaceuticals, Wayne, Pa.) has been approved by the FDA to treat hyperphosphatemia in ESRD subjects and it currently being marketed.
  • The above features and many other attendant advantages of the invention will be better understood by reference to the following detailed description.
    • 4. BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is an XRPD (x-ray powder diffraction) pattern of substantially pure hydrated lanthanum carbonate having a water content approximately equivalent to 4-5 moles of water.
  • FIG. 2 illustrates XRPD patterns of substantially pure corn starch, β-cyclodextrin, dextrates, D-sorbitol, D-mannitol, and anhydrous lanthanum carbonate.
  • FIG. 3 illustrates XRPD patterns of hydrated lanthanum carbonate at 60° C./95% RH (relative humidity) for 0, 1, 2, 3, 4, and 7 days.
  • FIG. 4 illustrates XRPD patterns of hydrated lanthanum carbonate at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 5 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/D-mannitol at 60° C./65% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 6 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/D-sorbitol at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 7 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/dextrates at 60° C./65% RH for 0, 1, 2, 3, 4, 7, 14, and 21 days.
  • FIG. 8 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/p-cyclodextrin at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 9 illustrates XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/corn starch at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 10 illustrates XRPD patterns of a 1:1 (by weight) mixture of anhydrous lanthanum carbonate/D-mannitol at 60° C./95% RH for 0, 1, 2, 3, 4, and 7 days.
  • FIG. 11 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/anhydrous lactose at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 12 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/lactose monohydrate at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 13 illustrates the XRPD patterns of a 1:1 (by weight) mixture of hydrated lanthanum carbonate/microcrystalline cellulose at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 14 illustrates the XRPD patterns of a 96:4 (by weight) mixture of hydrated lanthanum carbonate/D-mannitol at 60° C./95% RH for 0, 1, 2, 3, 4, 7, and 14 days.
  • FIG. 15 shows the degradation to lanthanum hydroxycarbonate that occurs in unformulated hydrated lanthanum carbonate and formulated hydrated lanthanum carbonate containing approximately 50% (by weight) dextrates at 25° C./60% RH, 30° C./60% RH, and 40° C./75% RH for up to 24 months.
    •  5. DETAILED DESCRIPTION OF THE INVENTION 5.1. General Definitions
  • As used herein, the terms “treat,” “treating,” or “treatment” mean the prevention, reduction, amelioration, partial or complete alleviation, or cure of hyperphosphatemia, chronic kidney disease (CKD), severe bone problems, soft tissue calcification, secondary hyperparathyroidism, or other as yet undiscovered conditions requiring control of phosphate absorption.
  • Further, as used herein, the term “subject” refers to a mammal (e.g., any veterinary medicine patient such as a domesticated animal, such as a dog or cat), or a human patient.
  • The terms “about” or “approximately” mean within an acceptable range for the particular parameter specified as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean a range of up to 20% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.
  • The term “dextrates” as used herein refers to a purified mixture of saccharides that is mostly dextrose (e.g., not less than about 93.0% and not more than about 99.0%, calculated on the dried basis) and that results from a controlled enzymatic hydrolysis of starch. Dextrates can be either anhydrous or hydrated. “Dextrates” can refer to dextrates as defined its official monograph found in National Formulary 21 (printed by Webcom Limited in Toronto, Canada; 2003). Dextrates are available from JRS Pharma (Patterson, N.Y.) as Emdex®.
  • As used herein, a “stabilized composition” or “stabilized lanthanum carbonate composition” refers to a composition containing lanthanum carbonate (of any hydration state including anhydrous lanthanum carbonate) and one or more monosaccharides or disaccharides. Preferably, the total amount of monosaccharides, disaccharides, or combination thereof is present in the stabilized composition in an amount of at least about 1% by weight. The lanthanum carbonate in a stabilized lanthanum carbonate composition degrades into lanthanum hydroxycarbonate at a slower rate compared to lanthanum carbonate alone or not in the presence of other materials. For example, after 7 days at 60° C. and 95% relative humidity, lanthanum carbonate in a lanthanum carbonate composition stabilized with at least about 4% monosaccharide, disaccharide, or combination thereof does not detectably (by present analytical techniques) degrade into lanthanum hydroxycarbonate. In contrast, under the same conditions, substantially pure lanthanum carbonate begins to decompose into lanthanum hydroxycarbonate after only 1 day.
  • A “pharmaceutically effective amount” or “therapeutically effective amount” as used herein is an amount or dose of lanthanum carbonate sufficient (i) to detectably decrease the serum phosphate levels of a subject or (ii) at a minimum, to keep the serum phosphate levels of a subject substantially constant.
  • “Lanthanum carbonate” as used herein encompasses all hydrated forms of lanthanum carbonate as well as anhydrous lanthanum carbonate.
  • “Percent” or “%” as used herein refers to the percentage by weight of the total composition.
  • The term “substantially pure lanthanum carbonate” refers to lanthanum carbonate of about 90% purity or greater, on an anhydrous basis.
  • The term “symptom(s)” of those at risk for or having hyperphosphatemia, CKD, soft tissue calcification associated with CKD, or secondary hyperparathyroidism may be any functional or structural abnormality experienced by a subject and indicating kidney dysfunction, e.g., those described in Section 5.6, infra. Among other abnormalities, as an example, one or more of the following symptoms may indicate risk for or the presence of CKD: a creatinine concentration of above about 1.6 mg/dL, a blood urea nitrogen (BUN) of above about 20 mg/dL, a blood phosphate level of above about 4.5 mg/dL, any detectable amount of blood in the urine, a urine protein concentration above about 100 mg/dL, a urine albumin concentration above about 100 mg/dL, an intact parathyroid hormone (PTH) concentration in the blood of above about 150 pg/mL, or a glomerular filtration rate (GFR) of below about 90 mL/min/1.73 m2.
    • 5.2. Lanthanum Carbonate
  • The stabilized compositions of the invention can contain lanthanum carbonate having the general formula La2(CO3)3.xH2O, wherein x has a value from 0 to 10. Preferably, x has a value from 3 to 8, desirably from 3 to 6. Most preferably, x may have an average value of about between 4 and 5. The hydration level of the lanthanum compound can be measured by methods well known in the art, such as thermo gravimetric analysis (TGA) or x-ray powder diffraction (XRPD).
  • Lanthanum carbonate has a tendency to degrade via decarboxylation to lanthanum hydroxycarbonate as shown:

  • La2(CO3)3+H2O→2LaOHCO3+CO2
  • The hydroxycarbonate product results from electrophilic or nucleophilic attack on the carbonyl moiety of lanthanum carbonate. This process is accelerated in the presence of moisture or heat and appears to be self-catalyzing. Hence, even a very small amount of lanthanum hydroxycarbonate in lanthanum carbonate formulations causes rapid and excessive degradation. Furthermore, there is a need in the art to prevent this degradation since, as noted above, current regulatory requirements preclude detectable decarboxylation for administration to patients. As a result, formulations that eliminate or substantially retard degradation are highly preferred.
  • In accordance with the present invention, the presence of at least about 1% by weight of one or more monosaccharides or disaccharides in the lanthanum carbonate composition significantly retards the degradation of lanthanum carbonate. Surprisingly, the addition of such a stabilizing agent is effective to minimize degradation irrespective of the degree of hydration (if any) of the lanthanum carbonate. For example, while unformulated lanthanum carbonates degrade to lanthanum hydroxycarbonate within about 9-12 months at room temperature, in the presence of a mono- or disaccharide (about 70% by weight), substantially no detectable degradation occurs for up to or more than 3 years under standard ambient conditions.
  • Without being bound by any theory, the stabilizing effect of the monosaccharide and disaccharide stabilizing agents of this invention is believed to be attributed to the availability of reactive alcohol —OH groups on such materials; on the other hand, polysaccharides (wherein the alcohol groups are further reacted to link the monosaccharide units) do not exhibit such stabilizing characteristics. Water reacts preferentially with the available alcohol groups on the monosaccharides or disaccharides, leaving the carbonyl groups of the lanthanum carbonate intact so that the anti-hyperphosphatemic agent is not degraded.
  • The degradation of lanthanum carbonate into lanthanum hydroxycarbonate can be observed by examining an x-ray powder diffraction (XRPD) pattern of a potentially degraded lanthanum carbonate sample. The presence of observable peaks corresponding to lanthanum hydroxycarbonate in the sample pattern indicates degradation whereas the absence of observable peaks indicates no detectable degradation. Example 5 demonstrates the use of XRPD patterns to observe the degradation of lanthanum carbonate into lanthanum hydroxycarbonate.
  • Additional advantages of the instant invention include, but are not limited to, less expensive storage and handling costs due to a diminished need to refrigerate the stabilized lanthanum carbonate formulations. The stabilized formulations also provide enhanced product shelf-life resulting in less waste due to outdated product inventory.
  • Other advantages of the presently disclosed formulations can be found in the parent application (U.S. application Ser. No. 10/926,330) and include that formulating lanthanum carbonate with a mono- or disaccharide increases the palatability of the formulation and allows the formulation to be administered in chewable form without liquid.
    • 5.3. The Monosaccharide and Disaccharide Stabilizing Agent
  • The stabilized compositions of the invention contain at least one monosaccharide or disaccharide. The monosaccharide, disaccharide, or mixture thereof is present in a total amount of at least about 1%, preferably from about 4% to about 90%, and more preferably from about 30% to about 70% by weight of the composition.
  • Suitable monosaccharides for use as stabilizing agents in the formulation of the present invention include, but are not limited to, glyceraldehyde, erythrose, threose, ribose, lyxose, xylose, arabinose, allose, talsoe, gulose, mannose, glucose (e.g., in the form of corn syrup), idose, galactose, altrose, dihydroxyacetone, erythrulose, ribulose, xyloketose, psicose, tagatose, sorbose, fructose, sorbitol, xylitol, inositol, erythritol, and mannitol in either the D- or L-configuration, including derivatives and analogs thereof. Monosaccharides for use in this inventions can be either cyclic (in either α- or β-form) or acyclic and can be used in the invention as mixtures. Other suitable monosaccharides include dextrose (D-glucose such as Cerelose® available from Fisher Scientific (Hampton, N.H.)).
  • Suitable disaccharides for use as stabilizers in the present invention include, but are not limited to, sucrose (for example, in the form of Di-Pac® available from Domino Foods in Baltimore, Md., Sugartab® available from JRS Pharma (Patterson, N.Y.), confectioner's sugar, or Nutab), lactose (including anhydrous lactose and lactose monohydrate), maltose, isomaltose, cellobiose, trehalose, maltitol (in the form of Lycasin® available from Roquette (Lestrem, France)), isomalt, lactitol, mixtures, dervatives, and analogs thereof. Disaccharides of this invention also include any combination of two monosaccharides linked by a glycosidic bond. Disaccharides can be either homodisaccharides (i.e., consisting of 2 monosaccharides that are the same) or heterodisaccharides (i.e., consisting of 2 monosaccharides that are different). Furthermore, monosaccharides and disaccharides can be used in the same formulation.
  • Other suitable monosaccharides and disaccharides can be found in Remington: The Science and Practice of Pharmacy (20th Edition, A. R. Gennaro editor, Lippincott Baltimore, Md.: Williams and Wilkins, 2000) at pages 409-413; and in Biochemistry (2nd Edition, Voet and Voet, New York: John Wiley & Sons, Inc., 1995) at pages 251-276. Hydrolyzed starches containing mono- and/or dissaccharides can also be used in the formulations of the invention.
  • Dextrates or sorbitol are preferably used as the monosaccharide or disaccharide stabilizing agent, in an amount preferably from about 4% to about 90% by weight of the formulation. In a preferred embodiment of the formulation of the invention, dextrates is incorporated as the stabilizing agent in an amount of about 70% by weight of the formulation. In another preferred embodiment of the formulation of the invention, sorbitol is incorporated as the stabilizing agent in an amount of about 30% by weight of the formulation.
    • 5.4. Excipients
  • The stabilized formulations of the invention may further comprise at least one excipient. The excipients used in the formulation administered by the present invention should be suitable for oral administration to renally impaired subjects The excipients may include diluents, binders, and lubricants/glidants. Other agents such as disintegrants, colors, and flavors/sweeteners can be added to the formulation.
  • Suitable diluents can be chosen from, for example, calcium sulfate dihydrate, oligosaccharide, isomaltooligosaccharide, erythritol, polydextrose, dextrins, starch, maltodextrin, calcium lactate trihydrate, microcrystalline cellulose (such as Avicel® available from GFS Chemicals (Powell, Ohio)), hydrolyzed cereal solids (such as Maltrons or Mor-Rex™), amylose, or glycine. Additional diluents can include the mono- and disaccharides stabilizing agents discussed, supra. One or more diluents can be present in a formulation. The total diluent amount can be from about 1% to about 90%, preferably from about 4% to about 90%, and most desirably from about 40% to about 80% by weight of the composition.
  • Useful lubricants can be chosen from, for example, magnesium stearate, talc, polyethylene glycol, silica, colloidal anhydrous silica, colloidal silicon dioxide, hydrogenated vegetable oil, glyceryl behenate or glyceryl monostearate. One or more lubricants can be present in a formulation. The total lubricant amount can be from about 0.1% to about 6.0%, preferably from about 0.1% to about 5.0%, and most desirably from about 0.1% to about 4.0% by weight of the composition.
  • Useful glidants can be chosen from, for example, silica, colloidal anhydrous silica, colloidal silicon dioxide, or talc. One or more glidants can be present in a formulation. The total glidant amount can be from about 0.1% to about 6.0%, preferably from about 0.1% to about 5.0%, and most desirably from about 0.1% to about 4.0% by weight of the composition.
  • It may also be advantageous to incorporate an antioxidant, for example, ascorbic acid, alpha tocopherol or butylated hydroxyanisole in the formulation to enhance its storage life. One or more antioxidants can be present in the formulation. The total antioxidant amount can be from about 0.0001% to 1.0%, preferably from about 0.001% to about 0.1%, and most desirably from about 0.005% to 0.05% by weight of the composition.
    • 5.5. Additional Active Ingredients 5.5.1. A Combination Formulation Comprising Lanthanum Carbonate and Vitamin D
  • Often, a subject suffering from hyperphosphatemia or the symptoms of CKD is also vitamin D deficient. Levels of 25-hydroxy vitamin D2 are low at values less than about 16 ng/mL and replacement treatment aims for levels of greater than or equal to about 16 ng/mL. Levels of 1,25-dihydroxy vitamin D2 are low at values less than about 22 pg/mL and replacement treatment aims for levels of greater than about 22 pg/mL. Thus, it becomes desirable to produce and administer to a patient a formulation containing lanthanum carbonate and vitamin D or an analog of vitamin D.
  • Examples of vitamin D sources which may be used in a formulation of this invention include 1,25 dihydroxy-vitamin D, the active metabolite of vitamin D (ealcitriol, rocalcitrol). Examples of suitable vitamin D analogs include doxercalciferol (Hectorole, available from Bone Care International, Middleton, Wis.) and paricalcitol (Zemplar®, available from Abbott Laboratories, Abbott Park, Ill.). One or more vitamin D sources or vitamin D analogs can be present in a formulation.
  • Vitamin D can also be administered in a separate dosage form, but concurrently with the dosage form of this invention. In a specific embodiment, 100 USP units of vitamin D is administered once per day and 250 mg of the stabilized lanthanum carbonate formulation is administered three times per day to a patient requiring treatment.
    • 5.5.2. A Combination Formulation Comprising Lanthanum Carbonate and a Calcium Source
  • Hyperphosphatemic subjects or subjects having symptoms of CKD often suffer from hypocalcaemia (i.e., a blood calcium concentration below about 8.5 mg/dL). Hence, a formulation of the invention can include lanthanum carbonate and a calcium source.
  • Examples of forms of calcium include calcium carbonate (e.g., Tums® available from GlaxoSmithKline, Uxbridge, UK), calcium acetate (e.g., PhosLo® available from Nabi Biopharmaceuticals, Boca Raton, Fla.), and CaCl2. One or more calcium sources can be present in a formulation.
  • A calcium source can also be administered in a separate dosage form, but concurrently with the dosage form of this invention. In a specific embodiment, 1-2 tablets containing 200 mg as calcium and 250 mg of the stabilized lanthanum carbonate formulation are each given 3 times per day to a patient requiring treatment.
    • 5.5.3. A Combination Formulation Comprising Lanthanum and Vitamin K
  • A subject suffering from hyperphosphatemia or the symptoms of CKD can be vitamin K deficient. In another embodiment of the present invention, the formulation of the invention, in combination with vitamin K, is administered to a subject suffering from hyperphosphatemia or the symptoms of CKD to alleviate vitamin K deficiency.
  • Examples of vitamin K sources include vitamin K1 (phylloquinone), vitamin K2 (menaquinone), and vitamin K3 (menadione).
  • Vitamin K can be combined in the same formulation as the lanthanum formulation or can be given in a different formulation. In a specific embodiment, 2.5 to 25 mg of vitamin K1 are administered once per day and a lanthanum formulation is administered three times per day to a subject requiring treatment.
    • 5.6. Subjects Treated with Stabilized Lanthanum Carbonate Formulations
  • Subjects susceptible to or suffering from hyperphosphatemia, at risk for chronic kidney disease (CKD), having stage one to five CKD, susceptible to or suffering from soft tissue calcification associated with CKD, susceptible to or suffering from secondary hyperparathyroidism, or susceptible to or suffering from other as yet undiscovered conditions requiring control of phosphate absorption, can be treated by administering a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present invention.
    • 5.6.1. Chronic Kidney Disease (CKM)
  • The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (“NKF-K/DOQI” or “K/DOQI,” as referred to herein) has defined chronic kidney disease (CKD) as either (1) having kidney damage as defined by structural or functional abnormalities of the kidney for 3 months or longer with or without a decreased glomerular filtration rate (GFR) or (2) having a GFR of less than 60 mL/min/1.73 m2 for 3 months or longer with or without kidney damage. Structural or functional abnormalities are manifested by symptoms such as either pathologic abnormalities or markers of kidney damage, including abnormalities identified in imaging studies or the composition of blood or urine.
  • Examples of markers of kidney damage include a plasma creatinine concentration of above about 1.6 mg/dL and a blood urea nitrogen (BUN) concentration of above about 20 mg/dL. Typically, both of these markers are elevated in individuals with CKD. Additional markers of kidney damage can include hematuria (i.e., any detectable amount of blood in the urine), proteinuria (i.e., protein concentrations in urine above about 100 mg/dL), albuminuria (i.e., albumin concentrations in urine above about 100 mg/dL), an intact parathyroid hormone (PTH) concentration in the blood above about 150 pg/mL, or blood phosphate levels of above about 4.5 mg/dL. One specific marker of kidney disease is a GFR rate above normal (i.e., a GFR above about 90 mL/min/1.73 m2), however a below normal GFR also indicates CKD.
  • K/DOQI has published guidelines that define five different stages of CKD (Am J Kidney Dis. 2001, 37(suppl 1):S1-S238). The following table provides a description of each of the five stages of CKD and the GFR ranges for each of the stages.
  • Five Stages of Chronic Kidney Disease (CKD)
    GFR
    Stage Description (mL/min/1.73 m2)
    At risk 90-120 (with
    CKD symptoms)
    1 Kidney damage with normal or elevated GFR ≧90
    2 Kidney damage with mildly reduced GFR 60-89
    3 Moderately reduced GFR 30-59
    4 Severely reduced GFR 15-29
    5 Kidney Failure (ESRD) <15 (or dialysis)
  • Hyperphosphatemia in CKD subjects has several secondary effects. When a subject suffers from hyperphosphatemia, excess serum phosphate precipitates serum calcium causing widespread ectopic extraskeletal calcification. Unwanted calcium deposits can occur in cardiovascular tissue, resulting in an increased risk of cardiovascular complications that often lead to death. Additionally, increased serum phosphate decreases intestinal calcium absorption. These two mechanisms work concurrently to reduce serum calcium levels.
  • A reduction in serum calcium levels can contribute to an increase in the production of parathyroid hormone (PTH) and to the development of secondary hyperparathyroidism. Furthermore, recent studies show that high phosphate levels can stimulate PTH production directly and lead to secondary hyperparathyroidism. Continual stimulation of PTH secretion induces hyperplasia of the parathyroid gland and may lead to a parathyroidectomy becoming necessary.
  • It is believed that the method of the present invention involving the administration of a stabilized lanthanum carbonate formulation not only reduces plasma phosphate levels but ameliorates the effects of CKDCl in subjects susceptible to or having any of stages one to five CKD, including hyperphosphatemia, ectopic extraskeletal calcification, serum hypocalcemia, and secondary hyperparathyroidism. It should however, be understood that this invention is not limited to any particular biochemical or physiological mechanism.
    • 5.6.2. Methods of Treating Hyperphosphatemia
  • Subjects susceptible to or suffering from hyperphosphatemia can be treated by administering a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the invention. Hyperphosphatemia as used herein refers to a condition of a patient having blood phosphate levels of above about 4.5 mg/dL.
    • 5.6.3. Methods of Treating Chronic Kidney Disease (CKD)
  • A subject having a symptom or symptoms of chronic kidney disease (CKD) can be treated by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present application. As indicated above, the subject treated may be at risk for CKD or have any of stages one to five CKD as defined above. Subjects at risk for CKD or who have any of stages one to five CKD who may be treated may have one or more of the following symptoms: a blood phosphate level of above about 4.5 mg/dL, a plasma creatinine concentration of above about 1.6 mg/dL, a BUN of above about 20 mg/dL, any detectable amount of blood in the urine, a urine protein concentration above about 100 mg/dL, a urine albumin concentration above about 100 mg/dL, an intact parathyroid hormone concentration in the blood above about 150 pg/mL, an abnormal GFR, or combination thereof.
  • The present method may be utilized to prevent the progression of renal pathology, e.g., by treating a subject displaying one or more symptoms of stage one CMD to prevent the development of CKD in the subject or by treating a subject having stage one CM) to prevent progression of the disease to stage two CKD, and so on.
    • 5.6.4. Methods of Preventing Calcification
  • A subject having a symptom or symptoms of CKD can be treated for calcification of soft tissue associated with CKD by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present invention.
  • Calcification can occur in any soft tissue. Soft tissue can include arterial tissue, cardiac muscle, heart valves, joints, skin and breast tissue.
    • 5.6.5. Methods of Treating Secondary Hyperparathyroidism
  • A subject suffering from or having one or more symptoms of secondary hyperparathyroidism can be treated by administering to the subject a therapeutically effective amount of a stabilized lanthanum carbonate formulation of the present application.
  • Hyperparathyroidism is defined as a disease in a subject having an intact PTH level of about 150 pg/mL or greater. The symptoms of hyperparathyroidism include hypocalcaemia (i.e., a blood calcium level below about 8.5 mg/dL), hyperphosphatemia (i.e., a blood phosphate level of above about 4.5 mg/dL), and bone disorders (e.g., bone fractures or bone pain).
    • 5.7. Administration of a Stabilized Lanthanum Carbonate Formulation
  • The lanthanum carbonate formulation can be orally administered to subjects in accordance with this invention in dosage forms varying from about 125 to about 2000 mg lanthanum carbonate as elemental lanthanum per meal. A typical dosage for an adult can be, e.g., 375 mg-6000 mg daily. More preferably, the dosage is 375-3750 mg/day. The dose can be divided and taken with each meal, for example a 250, 500, 750, or 1000 mg tablet, e.g., three times per day. Serum plasma levels can be monitored weekly and dosages can be modified until an optimal serum phosphate level is reached. Administration may be conducted in an uninterrupted regimen; such a regimen may be a long term regimen, e.g., a permanent regimen, for treating chronic conditions.
  • The lanthanum carbonate formulations can be orally administered, for example, in the form of tablets, capsules, chewable formulations, or the like. Frequently, due to their renal problems, subjects with hyperphosphatemia need to limit their liquid intake. Therefore, a lanthanum carbonate formulation that can be taken with no or limited amounts of liquid is desirable. For example, a lanthanum carbonate formulation, in the form of, e.g., beads, chewed or crushed tablets, powder, or sieved granules, may be sprinkled on food.
  • The lanthanum carbonate formulation is administered such that plasma levels of lanthanum are low, e.g., at least as low as those provided by a mean concentration curve where Cmax, Tmax and AUC are preferably less than 1.5 ng/ml, about 12 hours, and less than 50 ng·hr/ml, respectively, for a dose of 3 g per day (e.g., 1 g three times per day). Preferably, the Cmax and AUC are less than 1.1 ng/ml and less than 32 ng·hr/ml, and desirably, Cmax and AUC are less than 0.5 ng/ml and less than 20 ng·hr/ml, for such dosage. Tmax values are essentially unaffected by dose and Cmax and AUC values vary linearly with dosage for oral dosages up to about 1500 mg/day. Cmax and AUC values plateau for dosages above about 1500 mg/day. All of these parameters have their common meanings.
  • It will be understood that the type of lanthanum carbonate formulation and the duration of the treatment will vary depending on the requirements for treatment of individual subjects. The precise dosage regimen will be determined by the attending physician or veterinarian who will, inter alia, consider factors such as body weight, age and specific symptoms. The physician or veterinarian may titrate the dosage of lanthanum carbonate administered to a subject to determine the correct dosage for treatment. For example, a physician can measure phosphate levels in a patient, prescribe a particular lanthanum carbonate dosage to the patient for a week, and evaluate after the week if the dosage is appropriate by remeasuring phosphate levels in the patient.
    • 6. EXAMPLES
  • For the purposes of the Examples, the term “hydrated lanthanum carbonate” refers to lanthanum carbonate having a water content approximately equivalent to 4-5 moles of water.
    • 6.1. Example 1 Preparation of Stabilized Hydrated Lanthanum Carbonate Chewable Tablets (250 mg, 500 mg, 750 mg, and 1000 mg)
  • The manufacturing process involves sieving and blending the active ingredient with the excipients followed by direct compression. More specifically the steps are as follows:
  • a) Blend the lanthanum carbonate and the excipients (e.g., dextrates, colloidal silicon dioxide, talc (optional) and magnesium stearate).
  • b) Compress the blend using standard tooling to the target compression weight.
  • The following tablets were prepared as generally described above:
  • TABLE 1A
    Formulation A
    Ingredient 250 mg tablet 500 mg tablet Function
    Active Ingredient:
    Hydrated lanthanum 477.0 mg 954.0 mg Active
    (III) carbonate
    Other Ingredients:
    Dextrates 1247.0 mg 2494.0 mg Stabilizes
    lanthanum
    carbonate
    Colloidal anhydrous 36.0 mg 72.0 mg Improves
    silica blending and flow
    Purified talc 30.0 mg 60.0 mg Lubricant or
    glidant
    Magnesium stearate 10.0 mg 20.0 mg Lubricant
    Total 1800 mg 3600 mg
  • TABLE 1B
    Formulation B
    250 mg 500 mg 750 mg
    tablet tablet tablet 1000 mg tablet
    Tablet diameter
    Formulation 13 mm 18 mm 20 mm 22 mm
    Lanthanum 250 mg 500 mg 750 mg 1000 mg
    carbonate as
    elemental
    lanthanum
    Hydrated 477 mg 954 mg 1431 mg 1908 mg
    lanthanum
    carbonate
    Dextrates 533.2 mg 1066.4 mg 1599.6 mg 2132.8 mg
    (hydrated)
    Colloidal 21.2 mg 42.4 mg 63.6 mg 84.8 mg
    silicon dioxide
    Magnesium 10.6 mg 21.2 mg 31.8 mg 42.4 mg
    stearate
    Total weight 1042 mg 2048 mg 3126 mg 4168 mg
  • TABLE 1C
    Formulation C
    Percent by Weight
    Formulation Components in the Tablet
    Hydrated lanthanum carbonate 45.8%
    Colloidal silicon dioxide (e.g., Aerosil ® 2.1%
    200 available from Degussa Corp.
    (Piscataway, NJ))
    Dextrates 51.1%
    Magnesium sterate 1.0%
    • 6.2. Example 2 Stabilized Lanthanum Carbonate Chewable Tablet Formulation Containing Sorbitol Stabilizing Agent
  • The following lanthanum carbonate chewable tablet formulation comprising sorbitol can be manufactured as described in Example 1.
  • Percent by Weight
    Formulation Components in the Tablet
    Hydrated lanthanum carbonate 63.6%
    Glyceryl dibehenate 3.0%
    Colloidal silicon dioxide (e.g., Aerosil ® 2.0%
    200)
    Sorbitol 30.4%
    Talc 1.0%
    • 6.3. Example 3 Stabilized Lanthanum Carbonate Chewable Tablet Formulation Containing Mannitol Stabilizing Agent
  • The following lanthanum carbonate chewable tablet formulation comprising mannitol can be manufactured as described in Example 1.
  • Percent by Weight
    Formulation Components in the Tablet
    Hydrated lanthanum carbonate 63.6%
    Glyceryl dibehenate 3.0%
    Colloidal silicon dioxide (e.g., Aerosil ® 2.0%
    200)
    Mannitol 30.4%
    Talc 1.0%
    • 6.4. Example 4 Stabilized Lanthanum Carbonate Chewable Tablet Formulation Containing Xylitol Stabilizing Agent
  • The following lanthanum carbonate chewable tablet formulation comprising xylitol can be manufactured as described in Example 1.
  • Percent by Weight
    Formulation Components in the Tablet
    Hydrated lanthanum carbonate 63.6%
    Glyceryl dibehenate 3.0%
    Colloidal silicon dioxide (e.g., Aerosil ® 2.0%
    200)
    Xylitol 30.4%
    Talc 1.0%
    • 6.5. Example 5 The Stabilization of Lanthanum Carbonate Formulations with Monosaccharide and Disaccharide Stabilizing Agents
  • Excipient compatibility studies of hydrated lanthanum carbonate having a water content approximately equivalent to 4-5 moles of water and anhydrous lanthanum carbonate were performed to determine whether different classes of saccharide excipients would retard or prevent the appearance of decarboxylation products in thermally- and moisture-stressed solid lanthanum carbonate mixtures.
  • Conditions which would cause the formation of decarboxylation products in substantially pure hydrated lanthanum carbonate within one week were used. Mixtures of 1:1 or 96:4 (by weight) of hydrated lanthanum carbonate and a test excipient or 1:1 (by weight) anhydrous lanthanum carbonate and a test excipient were prepared and stressed, and samples were analyzed by XRPD (X-ray powder diffraction) as a function of exposure time.
    • 6.5.1. Materials and Methods 6.5.1.1 Samples and Reagents
  • Substantially pure hydrated lanthanum carbonate and anhydrous lanthanum carbonate samples were utilized for this study. Test excipients (D-mannitol, D-sorbitol, dextrates, γ-cyclodextrin, corn starch, anhydrous lactose, lactose monohydrate, and microcrystalline cellulose) were purchased from commercial suppliers and used as received.
    • 6.5.1.2 Mixture Preparation
  • Weighed samples of hydrated lanthanum carbonate/excipient (1:1 or 96:4 by weight) or anhydrous lanthanum carbonate/excipient (1:1 by weight) were sealed into scintillation vials and placed onto a Turbula mixer. Samples were mixed for ten minutes to ensure sample homogeneity.
    • 6.5.1.3 Humidity Chamber Preparation
  • Saturated salt solutions of Na2SO4.10H2O (˜95% RH (relative humidity)) or NaNO3 (65% RH) were prepared and placed into sealed chambers. The chambers were placed into a 60° C. oven overnight and the presence of solids was confirmed after 24 hours. These chambers were then subsequently used for the stressing studies of the various excipient/lanthanum carbonate mixtures. The lower humidity conditions were utilized for the D-sorbitol and dextrates excipients because they deliquesce under the more extreme conditions of 60° C./95% RH.
    • 6.5.1.4 X-Ray Powder Diffractometer (XRPD)
  • XRPD analyses were performed using a Shimadzu XRD-6000 X-ray powder diffractometer using Cu Kα radiation. Samples were prepared for analysis by placing them in an aluminum holder with a silicon insert.
    • 6.5.2. Results and Discussion 6.5.2.1 Characterization of Test Materials
  • The unstressed, substantially pure hydrated lanthanum carbonate was crystalline by XRPD (FIG. 1). Excipients and anhydrous lanthanum carbonate used in this study were characterized by XRPD for specificity purposes, and their patterns are displayed in FIG. 2. All excipients exhibit sufficient specificity to allow the monitoring of lanthanum hydroxycarbonate (HC) formation.
    • 6.5.2.2 Stress Studies of Hydrated Lanthanum Carbonate
  • At the experimental onset, the hydrated lanthanum carbonate was stressed under two conditions, 60° C./95% RH and 60° C./65% RH, in order to establish a baseline for monitoring decarboxylation. Individual samples were pulled after 1, 2, 3, 4, and 7 days and immediately analyzed by XRPD. In addition, pulls were made at 14 and 21 days under the 60 C/65% RH condition.
  • FIG. 3 (60° C./95% RH conditions) and FIG. 4 (60° C./65% RH conditions) summarize the results. Under the 60° C./95% RH conditions, the decarboxylation product, HC, was initially seen after one day. When hydrated lanthanum carbonate was placed under 60° C./65% RH stress conditions, HC was again initially seen after a single day (FIG. 4).
    • 6.5.2.3 Stress Studies of Hydrated Lanthanum Carbonate/D-Mannitol (60° C./65% RH Conditions)
  • The 1:1 (by weight) mixtures of hydrated lanthanum carbonate/D-mannitol were stressed and analyzed over a two week period. The results are shown in FIG. 5. No decarboxylation of the hydrated lanthanum carbonate was seen over the entire length of the experiment.
    • 6.5.2.4 Stress Studies of Hydrated Lanthanum Carbonate/D-Sorbitol (60° C./65% RH Conditions)
  • The 1:1 (by weight) mixtures of hydrated lanthanum carbonate/D-sorbitol were stressed over a three week period. Results are summarized in FIG. 6. No decarboxylation of the hydrated lanthanum carbonate was seen over the entire length of the experiment.
    • 6.5.2.5 Stress Studies of Hydrated Lanthanum Carbonate/Dextrates (60° C./65% RH Conditions)
  • The 1:1 mixtures (by weight) of hydrated lanthanum carbonate/dextrates were stressed over a three week period. Results are summarized in FIG. 7. No decarboxylation of the hydrated lanthanum carbonate was seen over the entire length of the experiment.
    • 6.5.2.6 Stress Studies of Hydrated Lanthanum Carbonate/β-Cyclodextrin (60° C./95% RH Conditions)
  • The 1:1 (by weight) mixtures of hydrated lanthanum carbonate/β-cyclodextrin were stressed and analyzed over a two week period. The results are summarized in FIG. 8. The presence of the decarboxylation product HC was initially detected after 1 day of stressing.
    • 6.5.2.7 Stress Studies of Hydrated Lanthanum Carbonate/Corn Starch (60° C./95% RH Conditions)
  • The 1:1 (by weight) mixtures of hydrated lanthanum carbonate/corn starch were set up for stressing over a two week period. The results are summarized in FIG. 9. The presence of the decarboxylation product HC was initially detected after 1 day of stressing.
    • 6.5.2.8 Stress Studies of Anhydrous Lanthanum Carbonate/D-Mannitol (60° C./95% RH Conditions)
  • The 1:1 (by weight) mixtures of anhydrous lanthanum carbonate/D-mannitol were stressed and analyzed over a two week period. The results are summarized in FIG. 10. No decarboxylation of the anhydrous lanthanum carbonate was seen over the entire length of the experiment.
    • 6.5.2.9 Stress Studies of Hydrated Lanthanum Carbonate/Anhydrous Lactose and Hydrated Lanthanum Carbonate/Lactose Monohydrate (60° C./95% RH Conditions)
  • 1:1 (by weight) mixtures of hydrated lanthanum carbonate/anhydrous lactose and hydrated lanthanum carbonate/lactose monohydrate were stressed and analyzed over a two week period. The results are summarized in FIGS. 11 and 12 for hydrated lanthanum carbonate/anhydrous lactose and hydrate lanthanum carbonate/lactose monohydrate, respectively. No detectable decarboxylation of the hydrated lanthanum carbonate was observed in either mixture over the entire length of the experiment.
    • 6.5.2.10 Stress Studies of Hydrated Lanthanum Carbonate/Microcrystalline Cellulose (60° C./95% RH Conditions)
  • The 1:1 (by weight) mixture of hydrated lanthanum carbonate/microcrystalline cellulose showed evidence of the decarboxylation of hydrated lanthanum carbonate after a single day of stressing at 60° C. and 95% relative humidity. The results are summarized in FIG. 13.
    • 6.5.2.11 The Stabilization of Hydrated Lanthanum Carbonate in a 96:4 (By Weight) Hydrated Lanthanum Carbonate/D-Mannitol Mixture
  • A study of a 96:4 (by weight) hydrated lanthanum carbonate/D-mannitol mixture was performed using the methods described above. This mixture was stressed at 60° C. and 95% relative humidity for 14 days. The results are summarized in FIG. 14.
  • After 7 days of stressing, no decarboxylation of the hydrated lanthanum carbonate in the mixture was detected. After 14 days of stressing, only a trace amount of decarboxylation of the hydrated lanthanum carbonate in the mixture was detected.
    • 6.5.3. Conclusions
  • The results show that mono- and disaccharides, such as mannitol, sorbitol, lactose and dextrates, offer a stabilizing protection to formulations containing lanthanum carbonate (anhydrous and hydrated) in reducing or eliminating the decarboxylation to lanthanum hydroxycarbonate. Polysaccharides such as corn starch, beta-cyclodextrins and microcrystalline cellulose, do not offer such protection and so decarboxylation was seen in formulations containing such materials at a similar rate to the unformulated drug substance exposed to the same conditions.
    • 6.6. Example 6 Decarboxylation Rates of Hydrated Lanthanum Carbonate Under Ambient Conditions
  • Unformulated hydrated lanthanum carbonate and formulated hydrated lanthanum carbonate tablets containing approximately 50% (by weight) dextrates were exposed to the standard ICH stability conditions of 25° C./60% RH, 30° C./60% RH and 40° C./75% RH for a period up to 2 years. Samples were removed periodically over this time and tested for their lanthanum hydroxycarbonate content using x-ray powder diffraction.
  • FIG. 15 shows the decarboxylation rates of unformulated hydrated lanthanum carbonate and demonstrates significant degradation of the unformulated hydrated lanthanum carbonate at the standard ICH stability conditions of 25° C./60% RH, 30° C./60% RH and 40° C./75% RH. The degradation at the 25° C./60% RH condition results indicates the need to store the unformulated drug substance in refrigerated conditions in order to slow the degradation rate. In contrast, no decarboxylation can be detected in similarly stored tablets formulated with about 50% (by weight) dextrates as shown in FIG. 15.
  • This experiment demonstrates that the dextrates are stabilizing the hydrated lanthanum carbonate by preventing decarboxylation at standard ambient conditions.
  • The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
  • All references cited herein, including all patents, published patent applications, and published scientific articles and books, are incorporated by reference in their entireties for all purposes.

Claims (9)

1. A stabilized lanthanum carbonate composition comprising lanthanum carbonate having the general formula:

La2(CO3)3.xH2O
wherein x has a value from 0 to 10, in an amount effective to treat hyperphosphatemia, and at least one pharmaceutically acceptable monosaccharide or disaccharide stabilizer in an amount sufficient to stabilize lanthanum carbonate against substantial decarboxylation to lanthanum hydroxycarbonate, wherein the monosaccharide or disaccharide is sucrose, glucose, galactose, fructose, dextrose, ribose, maltose, sorbitol, xylitol, mannitol, lactose, dextrates, or a mixture thereof and is present in an amount of from about 20% to about 80% by weight based on the total weight of the composition.
2. The stabilized composition of claim 1, wherein the monosaccharide or disaccharide is dextrates, which is present in an amount of from about 40% to about 80% by weight based on the total weight of the composition.
3. The stabilized composition of claim 1, further comprising a lubricant.
4. The stabilized composition of claim 3, wherein the lubricant is magnesium stearate, talc, polyethylene glycol, silica, colloidal anhydrous silica, colloidal silicon dioxide, hydrogenated vegetable oil, glyceryl behenate or glyceryl monostearate.
5. The stabilized composition of claim 3, further comprising a glidant.
6. The stabilized composition of claim 5, wherein the glidant is silica, colloidal anhydrous silica, colloidal silicon dioxide, or talc.
7. The stabilized composition of claim 6, comprising the following ingredients:
Ingredient % by weight lanthanum carbonate 26.5 dextrates 69.3 colloidal silicon dioxide 2 talc 1.7 magnesium stearate 0.5
wherein the lanthanum carbonate is hydrated having a water content approximately equivalent to 4-5 moles of water.
8. The stabilized composition of claim 6, comprising the following ingredients:
Ingredient % by weight lanthanum carbonate 63.6 colloidal silicon dioxide 2 talc 1 sorbitol 30.4 glyceryl dibehenate 3.0
wherein the lanthanum carbonate is hydrated having a water content approximately equivalent to 4-5 moles of water.
9. The stabilized composition of claim 6, comprising the following ingredients:
Ingredient % by weight lanthanum carbonate 45.8 dextrates 51.1 colloidal silicon dioxide 2.1 magnesium sterate 1.0
wherein the lanthanum carbonate is hydrated having a water content approximately equivalent to 4-5 moles of water.
US12/100,224 2003-08-26 2008-04-09 Stabilized lanthanum carbonate compositions Abandoned US20080187602A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/100,224 US20080187602A1 (en) 2003-08-26 2008-04-09 Stabilized lanthanum carbonate compositions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US51707803P 2003-11-05 2003-11-05
US10/926,330 US7465465B2 (en) 2003-08-26 2004-08-26 Pharmaceutical formulation comprising lanthanum compounds
US11/272,569 US7381428B2 (en) 2003-08-26 2005-11-09 Stabilized lanthanum carbonate compositions
US12/100,224 US20080187602A1 (en) 2003-08-26 2008-04-09 Stabilized lanthanum carbonate compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/272,569 Continuation US7381428B2 (en) 2003-08-26 2005-11-09 Stabilized lanthanum carbonate compositions

Publications (1)

Publication Number Publication Date
US20080187602A1 true US20080187602A1 (en) 2008-08-07

Family

ID=37434215

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/272,569 Active US7381428B2 (en) 2003-08-26 2005-11-09 Stabilized lanthanum carbonate compositions
US12/100,224 Abandoned US20080187602A1 (en) 2003-08-26 2008-04-09 Stabilized lanthanum carbonate compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/272,569 Active US7381428B2 (en) 2003-08-26 2005-11-09 Stabilized lanthanum carbonate compositions

Country Status (16)

Country Link
US (2) US7381428B2 (en)
EP (1) EP1785141A1 (en)
JP (1) JP2009514940A (en)
KR (1) KR20080071170A (en)
CN (1) CN101378767A (en)
AR (1) AR056609A1 (en)
AU (1) AU2006313490A1 (en)
BR (1) BRPI0619673A2 (en)
CA (1) CA2626894A1 (en)
EA (1) EA200801275A1 (en)
IL (1) IL190858A0 (en)
NO (1) NO20082538L (en)
PE (1) PE20070821A1 (en)
TW (1) TW200733968A (en)
WO (1) WO2007054782A1 (en)
ZA (1) ZA200804852B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206358A1 (en) * 2005-02-10 2008-08-28 Ineos Healthcare Limited Pharmaceutically Active Compounds, their Manufacture, Compositions Containing them, and their Use
US20090317459A1 (en) * 2006-01-31 2009-12-24 Ineos Healthcare Limited Material
US20100203152A1 (en) * 2007-07-27 2010-08-12 Ineos Healthcare Kimited Mixed metal compounds used as antacids
US20100215770A1 (en) * 2007-10-16 2010-08-26 Maurice Sydney Newton Mixed metal compounds for treatment of hyperphosphataemia
US20110014301A1 (en) * 1997-09-19 2011-01-20 Ineos Healthcare Limited Metal compounds, mixed or sulphated, as phosphate binders
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US9066917B2 (en) 2009-08-03 2015-06-30 Cytochroma Development Inc. Mixed metal compound
US9566302B2 (en) 2010-02-04 2017-02-14 Opko Ireland Global Holdings, Ltd. Composition comprising mixed metal compounds and xanthan gum

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2004266050B2 (en) * 2003-08-26 2009-06-18 Takeda Pharmaceutical Company Limited Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
BRPI0513603A (en) * 2004-07-27 2008-05-13 Shire Pharmaceuticals Inc use of lanthanum hydroxycarbonate and pharmaceutical composition
AU2005295609A1 (en) * 2004-10-15 2006-04-27 Spectrum Pharmaceuticals, Inc. Phosphate binder with reduced pill burden
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8974824B2 (en) * 2008-03-26 2015-03-10 Mylan Laboratories Ltd. Lanthanum composition
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
DE112009002063T5 (en) 2008-08-22 2012-01-12 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use for treating hyperkalemia
PT2389070E (en) * 2009-01-21 2013-10-21 Mylan Inc Disintegrable formulations of lanthanum carbonate
AU2010313075A1 (en) * 2009-10-26 2012-05-31 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
CN103037870B (en) 2010-05-12 2016-05-25 斯派克托姆制药公司 Basic carbonate lanthanum, carbonic acid gas lanthanum and manufacture method and purposes
EP2441436A1 (en) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Easy to administer phosphate binder formulation
US9402808B2 (en) * 2011-01-19 2016-08-02 Panacea Biotec Limited Liquid oral composition of lanthanum salts
CN103145170A (en) * 2013-03-27 2013-06-12 吉首大学 Method for preparing lanthanum carbonate by reacting supercritical carbon dioxide and lanthanum oxide
JP2016147827A (en) * 2015-02-12 2016-08-18 株式会社三和化学研究所 Pharmaceutical formulations containing lanthanum carbonate hydrate
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6623753B2 (en) * 2015-12-28 2019-12-25 ニプロ株式会社 Orally disintegrating tablets containing lanthanum carbonate
JP2020033303A (en) * 2018-08-30 2020-03-05 コーアイセイ株式会社 Orally quick disintegrating tablet containing lanthanum carbonate and being stable
CN108969497A (en) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 A kind of lanthanum carbonate tablet composition and preparation method thereof
JP2022516567A (en) * 2019-01-04 2022-02-28 ケイデンス ファーマ アーセー Combination therapy with phosphorus adsorbent and vitamin K
WO2021101461A1 (en) * 2019-11-21 2021-05-27 Santa Farma İlaç Sanayi̇ A.Ş. Oral solid pharmaceutical compositions comprising lanthanum carbonate octahydrate
CN113244179B (en) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 Lanthanum carbonate tablet with good stability, preparation method and application thereof
CN115813867A (en) * 2022-12-01 2023-03-21 山东齐都药业有限公司 Lanthanum carbonate freeze-dried tablet and preparation method thereof

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298822A (en) * 1978-05-30 1981-11-03 Matsushita Electronics Corporation Folded fluorescent lamp and socket
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4877735A (en) * 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
US5824336A (en) * 1994-05-20 1998-10-20 Janssen Pharmaceutica, N.V. Chewable flubendazole tablets for companion animals
US5853758A (en) * 1992-01-13 1998-12-29 Pfizer Inc. Preparation of tablets of increased strength
US5968976A (en) * 1995-03-25 1999-10-19 Anormed Inc. Pharmaceutical composition containing selected lanthanum carbonate hydrates
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6337539B1 (en) * 1998-09-29 2002-01-08 Toshiba Lighting & Technology Corporation Low-pressure mercury vapor discharge lamp and illuminator
US20020051822A1 (en) * 2000-06-27 2002-05-02 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US20020155168A1 (en) * 2001-04-23 2002-10-24 Abrams Michael J. Use of rare earth compounds for the prevention of kidney stone disease
US20030186845A1 (en) * 2000-08-04 2003-10-02 Yasunori Yoshida Compositions for preventing urinary calculus
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
US20040029829A1 (en) * 2000-12-19 2004-02-12 Kouji Miyazaki External skin preparations and process for producing the same
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6703005B2 (en) * 2000-04-05 2004-03-09 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Process for the production of a deodorant or antiperspirant product
US20040120922A1 (en) * 2002-10-22 2004-06-24 Genzyme Corporation Method for promoting bone formation
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20050096438A1 (en) * 2003-11-03 2005-05-05 Symyx Therapeutics, Inc. Polyamine polymers
US20050131138A1 (en) * 2003-11-03 2005-06-16 Eric Connor Anion-binding polymers and uses thereof
US20050147580A1 (en) * 2003-11-03 2005-07-07 Eric Connor Anion-binding polymers and uses thereof
US20050174975A1 (en) * 2004-02-11 2005-08-11 Vicinity Messaging Corporation System and method for wireless communication between previously known and unknown users
US20050209423A1 (en) * 2004-03-22 2005-09-22 Symyx Therapeutics, Inc. Crosslinked amine polymers
US20050208080A1 (en) * 2002-01-24 2005-09-22 Heightman Nicholas J Formulation for the administration of medicinal substances
US20050220890A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220750A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Methods and compositions for treatment of ion imbalances
US20050220889A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050239901A1 (en) * 2003-11-03 2005-10-27 Chang Han T Crosslinked amine polymers
US20060121127A1 (en) * 2003-08-26 2006-06-08 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06705B2 (en) 1985-12-19 1994-01-05 旭化成工業株式会社 Phosphate ion fixing agent
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
DE3724188C2 (en) 1987-07-17 1995-05-18 Heinz Dr Gries Metal-containing oligosaccharide polysulfates, process for their preparation and pharmaceutical compositions containing them
JP3591886B2 (en) 1994-09-05 2004-11-24 シーシーアイ株式会社 Rare earth element accumulating microorganism
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
JP4612183B2 (en) 2000-12-27 2011-01-12 株式会社ヤクルト本社 External composition for skin and method for producing the same
JP4612180B2 (en) 2000-12-19 2011-01-12 株式会社ヤクルト本社 Skin preparation
AU2003229437A1 (en) 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
AU2004266050B2 (en) 2003-08-26 2009-06-18 Takeda Pharmaceutical Company Limited Pharmaceutical formulation comprising lanthanum compounds
CA2558029C (en) 2004-03-30 2013-05-07 Ilypsa, Inc. Ion binding polymers and uses thereof

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298822A (en) * 1978-05-30 1981-11-03 Matsushita Electronics Corporation Folded fluorescent lamp and socket
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4877735A (en) * 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
US5853758A (en) * 1992-01-13 1998-12-29 Pfizer Inc. Preparation of tablets of increased strength
US5824336A (en) * 1994-05-20 1998-10-20 Janssen Pharmaceutica, N.V. Chewable flubendazole tablets for companion animals
US5968976A (en) * 1995-03-25 1999-10-19 Anormed Inc. Pharmaceutical composition containing selected lanthanum carbonate hydrates
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6337539B1 (en) * 1998-09-29 2002-01-08 Toshiba Lighting & Technology Corporation Low-pressure mercury vapor discharge lamp and illuminator
US6703005B2 (en) * 2000-04-05 2004-03-09 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Process for the production of a deodorant or antiperspirant product
US20020051822A1 (en) * 2000-06-27 2002-05-02 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
US20030186845A1 (en) * 2000-08-04 2003-10-02 Yasunori Yoshida Compositions for preventing urinary calculus
US20040029829A1 (en) * 2000-12-19 2004-02-12 Kouji Miyazaki External skin preparations and process for producing the same
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US20020155168A1 (en) * 2001-04-23 2002-10-24 Abrams Michael J. Use of rare earth compounds for the prevention of kidney stone disease
US20050208080A1 (en) * 2002-01-24 2005-09-22 Heightman Nicholas J Formulation for the administration of medicinal substances
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20040120922A1 (en) * 2002-10-22 2004-06-24 Genzyme Corporation Method for promoting bone formation
US20060121127A1 (en) * 2003-08-26 2006-06-08 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US20050239901A1 (en) * 2003-11-03 2005-10-27 Chang Han T Crosslinked amine polymers
US20050096438A1 (en) * 2003-11-03 2005-05-05 Symyx Therapeutics, Inc. Polyamine polymers
US20050131138A1 (en) * 2003-11-03 2005-06-16 Eric Connor Anion-binding polymers and uses thereof
US20050147580A1 (en) * 2003-11-03 2005-07-07 Eric Connor Anion-binding polymers and uses thereof
US20050174975A1 (en) * 2004-02-11 2005-08-11 Vicinity Messaging Corporation System and method for wireless communication between previously known and unknown users
US20050209423A1 (en) * 2004-03-22 2005-09-22 Symyx Therapeutics, Inc. Crosslinked amine polymers
US20050220750A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Methods and compositions for treatment of ion imbalances
US20050220751A1 (en) * 2004-03-30 2005-10-06 Dominique Charmot Ion binding polymers and uses thereof
US20050220889A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220890A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242869B2 (en) 1997-09-19 2016-01-26 Opko Ireland Global Holdings, Ltd. Metal compounds mixed or sulphated, as phosphate binders
US20110014301A1 (en) * 1997-09-19 2011-01-20 Ineos Healthcare Limited Metal compounds, mixed or sulphated, as phosphate binders
US8568792B2 (en) 1997-09-19 2013-10-29 Cytochroma Development Inc. Metal compounds, mixed or sulphated, as phosphate binders
US20080206358A1 (en) * 2005-02-10 2008-08-28 Ineos Healthcare Limited Pharmaceutically Active Compounds, their Manufacture, Compositions Containing them, and their Use
US9168270B2 (en) 2006-01-31 2015-10-27 Opko Ireland Global Holdings, Ltd. Water-insoluble, iron-containing mixed metal, granular material
US9907816B2 (en) 2006-01-31 2018-03-06 Opko Ireland Global Holdings, Ltd. Water-insoluble, iron-containing mixed metal, granular material
US20090317459A1 (en) * 2006-01-31 2009-12-24 Ineos Healthcare Limited Material
US10201501B2 (en) 2007-07-27 2019-02-12 Opko Ireland Global Holdings, Ltd. Mixed metal compounds used as antacids
US20100203152A1 (en) * 2007-07-27 2010-08-12 Ineos Healthcare Kimited Mixed metal compounds used as antacids
US10155040B2 (en) 2007-10-16 2018-12-18 Opko Ireland Global Holdings, Ltd. Mixed metal compounds for treatment of hyperphosphataemia
US20100215770A1 (en) * 2007-10-16 2010-08-26 Maurice Sydney Newton Mixed metal compounds for treatment of hyperphosphataemia
US9314481B2 (en) 2009-08-03 2016-04-19 Opko Ireland Global Holdings, Ltd. Method
US9066917B2 (en) 2009-08-03 2015-06-30 Cytochroma Development Inc. Mixed metal compound
US9566302B2 (en) 2010-02-04 2017-02-14 Opko Ireland Global Holdings, Ltd. Composition comprising mixed metal compounds and xanthan gum
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US9023397B2 (en) 2010-12-01 2015-05-05 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8980327B2 (en) 2010-12-01 2015-03-17 Shire Llc Capsule and powder formulations containing lanthanum compounds

Also Published As

Publication number Publication date
EA200801275A1 (en) 2008-10-30
AU2006313490A1 (en) 2007-05-18
US20060121127A1 (en) 2006-06-08
TW200733968A (en) 2007-09-16
IL190858A0 (en) 2008-11-03
CN101378767A (en) 2009-03-04
EP1785141A1 (en) 2007-05-16
ZA200804852B (en) 2009-06-24
PE20070821A1 (en) 2007-09-22
CA2626894A1 (en) 2007-05-18
JP2009514940A (en) 2009-04-09
NO20082538L (en) 2008-06-06
AR056609A1 (en) 2007-10-17
BRPI0619673A2 (en) 2011-10-11
US7381428B2 (en) 2008-06-03
WO2007054782A1 (en) 2007-05-18
KR20080071170A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
US7381428B2 (en) Stabilized lanthanum carbonate compositions
US8263119B2 (en) Capsule formulations containing lanthanum compounds
CA2629036C (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
ES2950337T3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
US11278591B2 (en) Compositions comprising choline
JP2907299B2 (en) Pharmaceutical preparations that bind stomach acid
CZ17621U1 (en) Pharmaceutical formulation comprising lanthanum compounds
US9023397B2 (en) Capsule and powder formulations containing lanthanum compounds
EP2919744B1 (en) Effervescent tablet
Chin et al. The action of activated charcoal on poisons in the digestive tract
AU730675B2 (en) Stable, solid preparation comprising vitamin D3 and tricalcium phosphate
CN1415603A (en) Salt of leonurine and its preparation
ES2298262T3 (en) STABILIZATION OF FORMULATIONS OF SOLID THYROID PHARMACOS.
JPH05246855A (en) Solid preparation composition containing vitamin d3
JPH05246854A (en) Solid preparation composition containing vitamin d3
MXPA99008344A (en) Stable solid preparation containing vitamin d3 and tricalcium phosphate

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHIRE INTERNATIONAL LICENSING B.V., CANADA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE CHANGE OF ADDRESS NEW ADDRESS;ASSIGNORS:FERDINANDO, JOSEPHINE CHRISTINE;DAVIES, PETER NEIL;REEL/FRAME:022206/0954

Effective date: 20080418

AS Assignment

Owner name: SHIRE INTERNATIONAL LICENSING B.V., NETHERLANDS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION OF APPLICANT'S ADDRESS TO;ASSIGNORS:FERDINANDO, JOSEPHINE CHRISTINE;DAVIES, PETER NEIL;REEL/FRAME:022210/0158

Effective date: 20080418

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION